 |
市场调查报告书
商品编码
1085609
復发性多形性胶质母细胞瘤治疗市场：按治疗、按类型、按区域规模、份额、前景、机会分析-2022-2028Recurrent Glioblastoma Multiforme Treatment Market, by Treatment, by Type, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028 |
||||||
价格
简介目录
在预测区间内，预计脑肿瘤发病率的增加将推动治疗復发性胶质母细胞瘤復发性息肉的市场增长。市场上的领先公司正在加大对研发的投入，以开发、创造和商业化新药，并有望在不久的将来为全球市场创造有利的增长机会。然而，缺乏有效的治疗方法和有效预防肿瘤復发的药物预计将限制预测区间内的市场增长。
本报告对复发性多形性胶质母细胞瘤治疗的全球市场进行研究和分析，并提供有关市场促进者、抑制者、市场机会、治疗方法/类型/区域市场分析和企业概况的信息。
目录
第 1 章调查目标/先决条件
第二章市场概述
- 报告说明
- 市场定义和范围
- 执行摘要
- 市场细分：按处理方法
- 市场细分：按类型
- 市场细分：按地区
- 连贯的机会图 (COM)
第三章市场动态、监管和趋势分析
- 市场动态
- 促进因素
- 抑制器
- 市场机会
- 影响分析
- 復发性胶质母细胞瘤多态性治疗的技术进展
- 主要发展
- 收购、合作、伙伴关係
- 流行病学
- 赎回分析
- 管道分析
- 价格分析
- 处理算法
第 4 章全球復发性多形性胶质母细胞瘤市场：COVID-19 的影响
- COVID 之前的状态
- 疫情过后的需求
- 需要一种治疗復发性胶质母细胞瘤多态性的药物
- 建议和指南：由监管机构提供
第 5 章全球治疗□□復发性多形性胶质母细胞瘤的市场：按治疗（2017-2028 年（100 万美元））
- 简介
- 口服药
- 放射增敏剂
- 亚硝基尿类药物
- 化疗
第 6 章全球治疗□□復发性多形性胶质母细胞瘤的市场：按类型（2017-2028 年（100 万美元））
- 简介
- 二级或三级
- 四级
- 其他
第 7 章全球復发性多形性胶质母细胞瘤治疗市场：按地区划分（2017-2028 年（100 万美元））
- 简介
- 北美
- 欧洲
- 亚太地区
- 拉丁美洲
- 非洲
- 中东
第8章竞争态势
- 公司简介
- GlaxoSmithKline, Plc.
- Astrazeneca
- F. Hoffman-La Roche, Ltd.
- Pfizer, Inc.
- Merck & Co., Inc.
- Vascular Biogeneics
- AngioChem, Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Boston Biomedical, Inc.
- Cantex Pharmaceuticals, Inc.
- Celldex Therapeutics, Inc.
- Cavion LLC
- Coherus BioSciences, Inc.
- Eisai
- Eli Lilly and Company
- Cortice Biosciences, Inc.
- EnGeneIC Ltd.
- GenSpera, Inc.
- ERC Belgium SA
- Genzyme Corporation
- ImmunoCellular Therapeutics, Ltd.
- GW Pharmaceuticals Plc.
第9章 章节
简介目录
Product Code: CMI682
Glioblastoma multiforme or GBM is an aggressive and the most common form of brain cancer that involves glial cells. Gliomas are rapidly developing tumors that develop from the star-shaped glial cells present in the spinal cord or brain. Recurrent glioblastoma multiforme is a possibility of reoccurrence of GBM after tumor surgery. This is because it is difficult to wholly remove the tumor during surgery and there is always a possibility that after a period of remission, cancer might recur. The symptoms of GBM include constant headaches, seizures, vomiting, difficulty in speaking, and double or blurred vision.
Market Dynamics
The rising incidence of brain cancers is expected to drive the recurrent glioblastoma multiforme treatment market growth over the forecast period. Although, researchers believe that egentic mutations may cause this disease, symptoms include seizures, change in mood, loss of appetite, double or blurred vision, change in ability to think and difficulty in speech. According to the statistics provided by the World Health Organization (WHO), each year, around 5 million people are diagnosed with epilepsy across the globe.
Moreover, tuberous sclerosis, neurofibromatosis, von-hippel-lindau disease, turcot syndrome, and Li-fraumeni syndrome are some of the genetic disorders related to the increasing prevalence of gliomas, which is expected to fuel the market growth during the forecast period.
Furthermore, key players in the market are increasingly investing in research & development to develop, create, and commercialize novel drugs, which is expected to create lucrative growth opportunities for the global recurrent glioblastoma multiforme treatment market in the near future. However, lack of effective therapies and the inability of drugs to effectively prevent tumor reoccurrence are predicted to restrict the market growth over the forecast period.
Key features of the study:
- This report provides in-depth analysis of the global recurrent glioblastoma multiforme treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
- It elucidates potential revenue opportunity across different segments and explains an attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global recurrent glioblastoma multiforme treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
- Key players covered as a part of this study include GlaxoSmithKline plc., AstraZeneca, F. Hoffman-La Roche, Ltd., Pfizer, Inc., Merck & Co., Inc., Vascular Biogeneics, AngioChem, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Boston Biomedical, Inc., Cantex Pharmaceuticals, Inc., Celldex Therapeutics, Inc., Cavion LLC, Coherus BioSciences, Inc., Eisai, Eli Lilly and Company, Cortice Biosciences, Inc., EnGeneIC Ltd., GenSpera, Inc., ERC Belgium SA, Genzyme Corporation, ImmunoCellular Therapeutics, Ltd., and GW Pharmaceuticals Plc.
- Insights from this report would allow marketers and management authorities of companies to make an informed decision with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global recurrent glioblastoma multiforme treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for recurrent glioblastoma multiforme treatment market, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
- Global Recurrent Glioblastoma Multiforme Treatment Market, By Treatment:
- Oral Medications
- Radiosensitizers
- Nitrosoureas Drugs
- Chemotherapy
- Global Recurrent Glioblastoma Multiforme Treatment Market, By Type:
- Grade II or Grade III
- Grade IV
- Others
- Global Recurrent Glioblastoma Multiforme Treatment Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Treatment:
- Oral Medications
- Radiosensitizers
- Nitrosoureas Drugs
- Chemotherapy
- By Type:
- Grade II or Grade III
- Grade IV
- Others
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Treatment:
- Oral Medications
- Radiosensitizers
- Nitrosoureas Drugs
- Chemotherapy
- By Type:
- Grade II or Grade III
- Grade IV
- Others
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Treatment:
- Oral Medications
- Radiosensitizers
- Nitrosoureas Drugs
- Chemotherapy
- By Type:
- Grade II or Grade III
- Grade IV
- Others
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Treatment:
- Oral Medications
- Radiosensitizers
- Nitrosoureas Drugs
- Chemotherapy
- By Type:
- Grade II or Grade III
- Grade IV
- Others
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Treatment:
- Oral Medications
- Radiosensitizers
- Nitrosoureas Drugs
- Chemotherapy
- By Type:
- Grade II or Grade III
- Grade IV
- Others
- Africa
- By Region:
- North Africa
- Central Africa
- South Africa
- By Treatment:
- Oral Medications
- Radiosensitizers
- Nitrosoureas Drugs
- Chemotherapy
- By Type:
- Grade II or Grade III
- Grade IV
- Others
- North America
- Company Profiles
- GlaxoSmithKline, Plc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Astrazeneca
- F. Hoffman-La Roche, Ltd.
- Pfizer, Inc.
- Merck & Co., Inc.
- Vascular Biogeneics
- AngioChem, Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Boston Biomedical, Inc.
- Cantex Pharmaceuticals, Inc.
- Celldex Therapeutics, Inc.
- Cavion LLC
- Coherus BioSciences, Inc.
- Eisai
- Eli Lilly and Company
- Cortice Biosciences, Inc.
- EnGeneIC Ltd.
- GenSpera, Inc.
- ERC Belgium SA
- Genzyme Corporation
- ImmunoCellular Therapeutics, Ltd.
- GW Pharmaceuticals Plc.
- GlaxoSmithKline, Plc.
"*" marked represents similar segmentation in other categories in the respective section
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Treatment
- Market Snippet, By Type
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Technological Advancements in Recurrent Glioblastoma Multiforme Treatment
- Key Developments
- Acquisition, Collaborations & Partnerships
- Epidemiology
- Reimbursement Analysis
- Pipeline Analysis
- Pricing Analysis
- Treatment Algorithm
4. Global Recurrent Glioblastoma Multiforme Treatment Market, Impact of Coronavirus (Covid-19) Pandemic
- Pre-COVID Situation
- Post-COVID Demand
- Need for Recurrent Glioblastoma Multiforme Treatment
- Recommendations and Guidelines by Regulatory Bodies
5. Global Recurrent Glioblastoma Multiforme Treatment Market, By Treatment, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Oral Medications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Radiosensitizers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Nitrosoureas Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
6. Global Recurrent Glioblastoma Multiforme Treatment Market, By Type, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Grade II or Grade III
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Grade IV
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
7. Global Recurrent Glioblastoma Multiforme Treatment Market, By Region, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, By Region, 2017 - 2028
- Regional Trends
- North America
- Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- GCC
- Israel
- Rest of Middle East
8. Competitive Landscape
- Company Profiles
- GlaxoSmithKline, Plc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Astrazeneca
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- F. Hoffman-La Roche, Ltd.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Pfizer, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Merck & Co., Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Vascular Biogeneics
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- AngioChem, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Boehringer Ingelheim GmbH
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Boston Biomedical, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Cantex Pharmaceuticals, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Celldex Therapeutics, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Cavion LLC
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Coherus BioSciences, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Eisai
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Eli Lilly and Company
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Cortice Biosciences, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- EnGeneIC Ltd.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GenSpera, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- ERC Belgium SA
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Genzyme Corporation
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- ImmunoCellular Therapeutics, Ltd.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GW Pharmaceuticals Plc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
9. Section
- References
- Research Methodology
- About us and Sales Contact
02-2729-4219
+886-2-2729-4219
